57 results about "Extended release tablets" patented technology

The invention belongs to the technical field of pharmaceutical preparations, relates to a metformin hydrochloride sustained-release tablet and a preparation method thereof, and aims to overcome the technical defects of insufficient release behavior regulation and control precision and poor stability of an existing metformin hydrochloride sustained-release preparation. The metformin hydrochloride sustained-release tablet disclosed by the invention takes metformin hydrochloride as an effective component, is matched with sustained-release materials including hydroxypropyl methyl cellulose, propylene carbonate, zein, a filling agent, an adhesive and a lubricating agent, and can be selectively matched with a gastric-soluble film coating material. According to the invention, the stable release of the medicine is realized, the initial burst release phenomenon is avoided, meanwhile, the stability of the preparation is remarkably improved, and the good slow release performance can still be maintained after long-term storage.

1.The name of the design product: packaging box (Alican Ning salted hydrochloric acid dimethyl aniline sustained-release tablet). 2.The use of the design product: used for the outer packaging of medicines. 3.The design points of the design product: the combination of shape, pattern and color. 4.The picture or photo that best shows the design points: front view. 5.The design contains colors.

The application provides a bupropion hydrochloride sustained-release tablet and a preparation method, and belongs to the technical field of pharmacy. The pharmaceutical composition contains 150 parts of bupropion hydrochloride, 122.5-157.5 parts of glycerin monostearate, 17.5-22.5 parts of triethyl citrate, 68-104 parts of microcrystalline cellulose and 2-6 parts of magnesium stearate, wherein the bupropion hydrochloride raw material and the glycerin monostearate and the triethyl citrate are prepared into a solid dispersion through a hot melt extrusion process. The application provides a bupropion hydrochloride sustained-release tablet which is stable in drug release, slow in growth of related substances, does not need to be coated and can be taken and eaten, and a preparation method.

The invention discloses a method for preparing trazodone hydrochloride sustained-release tablets through a centrifugal granulation process. The method comprises the following steps: S1, crushing trazodone hydrochloride and sieving; s2, weighing trazodone hydrochloride, a sustained-release material and a filling agent according to the prescription dosage, adding the weighed materials into a centrifugal granulator for melting granulation at the granulation temperature of 90-100 DEG C, maintaining the temperature for mixing granulation, and cooling to room temperature for later use after the granulation is completed; s3, carrying out size stabilization on the granules, adding an adhesive, uniformly mixing, adding a lubricant, and uniformly mixing; the particles containing trazodone hydrochloride are obtained; and S4, tabletting the granules to obtain the trazodone hydrochloride sustained release tablets. The trazodone hydrochloride sustained-release tablet prepared by the method disclosed by the invention is high in hardness, low in friability and convenient to operate, and is more beneficial to product packaging, transportation and storage; the method adopts the centrifugal granulator, is more energy-saving and environment-friendly, and can greatly reduce the cost of manpower and material resources; the preparation method disclosed by the invention is good in reproducibility, is more beneficial to commercial production, and brings greater benefits to enterprises.

The invention provides a sitagliptin and metformin sustained-release pharmaceutical composition as well as a preparation method and application thereof, and relates to the technical field of sustained-release preparations. The pharmaceutical composition comprises a sustained-release tablet core and a quick-release coating layer, the sustained-release tablet core comprises an active ingredient metformin hydrochloride and a sustained-release framework material hydroxypropyl methylcellulose, and the sustained-release tablet core does not contain microcrystalline cellulose; the quick-release coating layer comprises an active component sitagliptin phosphate; the weight ratio of metformin hydrochloride to hydroxypropyl methylcellulose in the sustained release tablet core is 50: (24-27). The composition utilizes a double-layer structure to realize double-phase release of the medicine; the microcrystalline cellulose is removed, and the specific ratio of the active component to the framework material is limited, so that the moldability and ideal dissolution behavior of the preparation are ensured while the tablet weight is remarkably reduced to improve the swallowing compliance, and the technical problem that the slow-release framework function is difficult to maintain under the condition that the weight of a high-drug-loading-capacity compound preparation is greatly reduced is successfully solved.

The application discloses a dapagliflozin metformin sustained-release tablet, which comprises the following components: metformin hydrochloride, an isolation material, dapagliflozin propylene glycol monohydrate, a cosolvent, a lubricant, a diluent and a disintegrant. 90 The metformin hydrochloride is composed of three kinds of particles with different particle sizes, and the particle sizes D 90 of the three kinds of particles are 0.5-1.0 μm, 50-200 μm and 300-600 μm respectively. The weight composition ratio of the three kinds of particles is (0.5-1) : 1 : (0.5-1). The dapagliflozin metformin sustained-release tablet provided by the application has a longer action time, and can be uniformly and slowly released and chemically stable.

The application provides a sitagliptin and metformin hydrochloride sustained-release pharmaceutical composition and a preparation method and application thereof, and relates to the technical field of sustained-release preparations. The pharmaceutical composition comprises a sustained-release tablet core and a quick-release coating layer; the sustained-release tablet core comprises active ingredients metformin hydrochloride and a sustained-release matrix material hydroxypropyl methyl cellulose, and the sustained-release tablet core does not contain microcrystalline cellulose; the quick-release coating layer comprises active ingredients sitagliptin phosphate; the weight ratio of metformin hydrochloride to hydroxypropyl methyl cellulose in the sustained-release tablet core is 50:(24-27). The composition realizes double-phase release of drugs by using a double-layer structure; by removing the microcrystalline cellulose and limiting the specific ratio of active ingredients to the matrix material, the forming property of the preparation and the ideal dissolution behavior are ensured while the tablet weight is significantly reduced to improve the swallowing compliance, and the technical problem that a high drug loading compound preparation is difficult to maintain the function of the sustained-release matrix under a large amount of weight reduction is successfully solved.

The invention relates to a linagliptin and metformin sustained-release composition and a preparation method thereof, and relates to the technical field of pharmaceutical preparations, the linagliptin and metformin sustained-release composition comprises a metformin sustained-release tablet core and a linagliptin coating layer wrapping the metformin sustained-release tablet core; the linagliptin coating layer accounts for 2-3% of the total mass of the composition; the metformin sustained-release tablet core comprises a plain pellet core, a coating layer and a filling agent; wherein the plain pellet core comprises a large-particle-size pellet core of 1.10-1.25 mm, a medium-particle-size pellet core of 0.80-0.95 mm and a small-particle-size pellet core of 0.50-0.65 mm, and the mass ratio of the large-particle-size pellet core to the medium-particle-size pellet core to the small-particle-size pellet core is 15: 60: 25; through particle size grading, pore differentiation design and hydrophobic modification treatment, the drug release curve is optimized, the release uniformity is improved, and meanwhile, the production stability and the consistency of the preparation are improved.

The invention provides a sitagliptin and metformin sustained release tablet and a preparation method thereof. The sitagliptin and metformin sustained-release tablet sequentially comprises a metformin tablet core, a sitagliptin quick-release layer and a gastric-soluble coating layer from inside to outside, and the sitagliptin quick-release layer comprises sitagliptin phosphate monohydrate, a basic nitrogen atom shielding agent, hydroxypropyl methylcellulose, propyl gallate, kaolin and polyethylene glycol. Wherein the basic nitrogen atom shielding agent is mixed in the sitagliptin phosphate monohydrate and is used for shielding protection of trifluorophenylpiperazine ring tertiary nitrogen and beta-aminopropionic acid residue primary amino in the sitagliptin phosphate monohydrate. According to the sitagliptin and metformin sustained-release tablet, the dissolution rate of sitagliptin can be increased, so that the drug effect of the sitagliptin and metformin sustained-release tablet is ensured.

The invention relates to a dapagliflozin and metformin sustained-release tablet and a preparation method thereof, corresponding anti-spallation stabilizers are respectively added into dapagliflozin and metformin layer materials in a prescription, and the problems of temperature, humidity and spallation generated in the storage process can be reduced.

The invention discloses a gliquidone multilayer sustained-release tablet and a preparation method thereof, and belongs to the technical field of medical products, the gliquidone multilayer sustained-release tablet comprises a first tablet core and a second tablet core containing gliquidone, the first tablet core is coated with an isolation layer, and the isolation layer and the outer layer of the second tablet core are coated with an outer coating; the first tablet core comprises metformin, sodium bicarbonate, microcrystalline cellulose and resistant starch; the isolating layer comprises an enteric coating. The first tablet core is coated with the enteric coating, so that the dissolution property is greatly reduced under the acidic condition in the stomach, the stimulation of metformin to the stomach is reduced, and the comfort level of the stomach is improved; the metformin is gradually released in intestines; gliquidone is gradually released in gastrointestinal tracts, and is synergistically hypoglycemic with metformin; the resistant starch and the microcrystalline cellulose have a slow release effect, promote intestinal tract movement and improve the comfort of intestinal tracts; the sodium bicarbonate can absorb lactic acid rise caused by metformin accumulation.

The application discloses a sustained-release pregabalin composition and a preparation method thereof, and belongs to the technical field of medicine, and specifically relates to a sustained-release pregabalin composition and a preparation method thereof. The sustained-release pregabalin composition comprises the following components in parts by weight: 45-50 parts of pregabalin or a pharmaceutically acceptable salt thereof; 23-35 parts of a matrix forming agent; 23-30 parts of a swelling agent, wherein the swelling agent is a double-layer network structure, a first layer network provides support for a second layer network, and the two are crosslinked in a physical and chemical manner; 15-25 parts of a sustained-release agent; and 12-20 parts of a filling agent. The first layer network comprises chitosan, sodium alginate, methacrylic anhydride, a photoinitiator and zinc ions; and the second layer network comprises cyclodextrin, polyethylene glycol dimethacrylate, methacrylamide, a crosslinking agent, a photoinitiator and deionized water. The sustained-release tablet of the application is expanded to more than 13 mm after 1.5 h, and the tablet can remain intact, which is beneficial to the retention of the sustained-release pregabalin composition in the stomach, achieves the effect of sustained release, and improves the absorption of pregabalin.

The application discloses a sitagliptin and metformin sustained-release tablet and a preparation process thereof, and belongs to the technical field of medicines.A sitagliptin and metformin sustained-release tablet comprises the following components in percentage by weight: 30-35% of coated sitagliptin microcapsules, 58-62% of metformin granules, 5-10% of outer layer disintegrating agents and 0.5-1% of lubricants.The coated sitagliptin microcapsules, the metformin granules, the outer layer disintegrating agents and the lubricants are mixed first, and then tableting is carried out, so that the sitagliptin and metformin sustained-release tablet is obtained.The sitagliptin and metformin sustained-release tablet provided by the application has excellent moisture resistance and stability, and can guarantee the quality and curative effect of medicines.

The invention relates to the technical field of medicine analysis, and discloses a method for detecting the content of trazodone hydrochloride sustained release tablets and / or related substances. According to the detection method, the content of the trazodone hydrochloride sustained-release tablet and the content of impurities can be simultaneously determined through an HPLC method, the method is high in specificity, a blank solvent and a blank auxiliary material are not interfered at the retention time of a main peak and an impurity peak, and the separation degree of the main peak and each impurity is good; the method is good in precision and reproducibility, and can be operated by different instruments and personnel; the accuracy and the sensitivity are high, and a relatively low amount of impurities can be accurately detected; the durability is good, and the detection result is not influenced by the chromatographic condition and the small-range change of the solution. The content and related substances can be simultaneously detected, so that the detection efficiency can be obviously improved, and the manpower and material resource cost can be saved. The method adopts isocratic elution, is simple and convenient to operate and low in instrument configuration requirement, and can complete analysis by a single pump. The isocratic elution mobile phase condition is fixed, the baseline fluctuation is small, and the experimental result is stable and reliable.

The application provides a method for simultaneously determining the content of dapagliflozin and metformin, which adopts a reverse-phase high performance liquid chromatography method to separate and determine the content of dapagliflozin and metformin in dapagliflozin and metformin sustained-release tablets. The method has good separation degree, solvent does not interfere with detection, and good method specificity. The detection method is simple, rapid, accurate, high in sensitivity, good in repeatability and accuracy, can quickly and accurately perform qualitative and quantitative analysis on the content of dapagliflozin and metformin hydrochloride in dapagliflozin and metformin sustained-release tablets, and ensures the controllability of the quality of the product.

The invention relates to a detection method for simultaneously determining the contents of two main components in the dissolution rate of dapagliflozin and metformin sustained-release tablets. According to the detection method, two main components in the dissolution rate of the dapagliflozin and metformin sustained release tablet are simultaneously detected by using a high performance liquid chromatography of an ultraviolet detector. The detection method not only can solve the problem that the two main components cannot be simultaneously detected under a liquid chromatographic condition due to large polarity difference, but also provides a chromatographic system adopting an ion pair reagent, and the two components can be reserved and separated by adopting a common conventional C18 chromatographic column, so that the detection efficiency is greatly improved. The real and reliable quality of the dapagliflozin and metformin sustained release tablet is ensured. The method can quantitatively detect the contents of the two main components at the same time, and is good in separation degree, good in linearity, high in accuracy, high in practicability and simple and rapid in detection process.

The present application belongs to the field of medicine processing, and relates to a sustained-release tablet containing trazodone hydrochloride and a preparation method thereof. The sustained-release tablet is prepared from the following raw materials in parts by mass: 75-150 parts of active ingredient, 42-84 parts of filling agent, 12-24 parts of binding agent, 12-24 parts of release retardant, 3-6 parts of lubricant and wetting agent; the active ingredient is trazodone hydrochloride; the filling agent is one or more of sucrose, corn starch, lactose and microcrystalline cellulose; the binding agent is one or more of povidone K30, povidone K90 and hypromellose; the release retardant is one of Brazil palm wax, insect wax and lanolin; the lubricant is one or more of magnesium stearate, talc and silicon dioxide; and the wetting agent is one of purified water, 10% ethanol solution and propylene glycol solution. The method can solve the problem of particle caking and improve the dissolution behavior of the preparation.

This invention relates to a dapagliflozin-metformin extended-release tablet, which comprises a metformin hydrochloride tablet layer, a dapagliflozin tablet layer, and a gastrointestinal film coating. The metformin hydrochloride tablet layer contains 1000 mg of metformin hydrochloride, magnesium stearate, sodium carboxymethyl cellulose, hydroxypropyl methylcellulose 2208, and silicon dioxide. The dapagliflozin tablet layer contains 5-25 mg of amorphous dapagliflozin, 6-15 mg of sodium carboxymethyl starch, anhydrous lactose, microcrystalline cellulose, magnesium stearate, and silicon dioxide. The extended-release tablet of this invention exhibits good stability under high temperature, high humidity, and light exposure. This invention also provides a method for preparing the dapagliflozin-metformin extended-release tablet.

The invention discloses an isosorbide dinitrate sustained-release tablet and a preparation method thereof, sodium alginate is used as a sustained-release skeleton, lactose, calcium hydrophosphate and dextrin are used as filling agents, and the hydrophilicity of lactose is beneficial for water to rapidly permeate into the tablet to start medicine dissolution; the hydrophobic and rigid structure of the calcium hydrophosphate hinders rapid penetration of water and drug diffusion; partial dissolvability of dextrin can form local corrosion or channels; through combination of multiple aspects, the permeation rate and diffusion path of moisture and the corrosion / expansion degree of a tablet matrix can be adjusted, a more controllable and more stable drug release environment is constructed together, and the sustained release requirement is met.

The phencynonate hydrochloride sustained release tablet comprises the following components: phencynonate hydrochloride, a sustained release material, dodecanal, a 40% dimethylamine aqueous solution, sodium triacetoxyborohydride, an adhesive, a filler and a lubricant, the invention also relates to a preparation method of the phencynonate hydrochloride sustained release tablet. The sustained-release material is added to delay the release of the water-soluble phencynonyl hydrochloride, then lauric aldehyde and dimethylamine are further added to react in the presence of a reducing agent sodium triacetoxyborohydride to generate high-fat-solubility, low-toxicity and stable tertiary amine, and the tertiary amine and phencynonyl ester cations in the phencynonyl hydrochloride can form hydrophobic ion pairs; the release rate from the preparation to a water phase is slowed down, slow release of the medicine is realized, the action time is prolonged, the administration frequency is reduced, and the compliance to people taking vehicles for a long time is improved.

The invention discloses a pharmaceutical composition for reducing blood sugar and application thereof, and belongs to the technical field of preparation of drugs for reducing blood sugar. The pharmaceutical composition is prepared from the following components in parts by weight: 5 to 7 parts of empagliflozin, 30 to 40 parts of cortex cinnamomi extract, 500 to 700 parts of metformin, 60 to 80 parts of microcrystalline cellulose, 10 to 15 parts of polyvinylpolypyrrolidone, 100 to 120 parts of HPMC K100M, 50 to 60 parts of ethyl cellulose, 40 to 50 parts of Eudragit FS30D, 40 to 50 parts of soybean phospholipid and 10 to 20 parts of poloxamer 188. The composition is applied to preparation of sustained-release tablets for reducing blood sugar, and can reduce loss of islet cells and protect kidney functions and gastric mucosa.

The invention discloses a small sitagliptin-metformin sustained release tablet and a preparation method thereof, and belongs to the technical field of medical products, the sitagliptin-metformin sustained release tablet sequentially comprises a sustained release tablet core, an isolation layer, a quick release layer and an outer coating from inside to outside; the sustained release tablet core comprises metformin, resistant starch, microcrystalline cellulose and sodium bicarbonate; the isolating layer comprises an enteric coating. The sustained-release tablet core is coated with the enteric coating, so that the dissolution property is greatly reduced under the acidic condition in the stomach, the stimulation of metformin to the stomach is reduced, and the comfort level of the stomach is improved; and the metformin is gradually released in intestines. The product is small in size and weight, the swallowing experience is improved, and the situation that swallowing is difficult is reduced. The resistant starch and the microcrystalline cellulose have a slow release effect, promote intestinal tract movement and improve the comfort of intestinal tracts; meanwhile, lactic acid rise caused by metformin accumulation can be absorbed.

1. The name of the design product: packaging box (metformin hydrochloride sustained-release tablets). 2. The use of the design product: for product packaging. 3. The design features of the design product: the combination of shape and pattern. 4. The picture or photo that best indicates the design features: front view.

This invention discloses a guanifacine hydrochloride sustained-release tablet and its preparation method. The method includes placing a granulated / mixed, tableted guanifacine hydrochloride pharmaceutical composition into a hot air device for drying. The hot air device is selected from a coating machine or an oven, and the hot air temperature ranges from 30 to 70°C. After drying, the resulting guanifacine hydrochloride sustained-release tablet has a moisture content ≤4.0% by weight, preferably ≤3.5% by weight. The guanifacine hydrochloride pharmaceutical composition contains guanifacine hydrochloride, lactose, microcrystalline cellulose, hydroxypropyl methylcellulose, methacrylate copolymer, fumaric acid, glyceryl behenate, sodium stearate fumarate, and micronized silica gel. This hot air drying process effectively controls the total impurities of the guanifacine hydrochloride sustained-release tablets to ≤1.0% and the single impurities to ≤0.1%. This process improves the safety and stability of the drug, is easy to operate, and is suitable for commercial production.

The present disclosure discloses an Ivabradine hydrochloride sustained-release tablet and a preparation method thereof. The sustained-release tablet contains Ivabradine hydrochloride, a gel matrix sustained-release material, a pore-forming agent and a lubricating agent. The gel matrix sustained-release material is hydroxypropylmethyl cellulose. The pore-forming agent is selected from one or a mixture of microcrystalline cellulose and lactose. The lubricating agent is selected from one or a mixture of colloidal silica and magnesium stearate. The sustained-release tablet just needs to be orally administered once a day to reduce the peak-trough concentration fluctuations, thereby reducing the frequency of medication administration for patients and improve the medication compliance of the patients.

The invention relates to application of a coating premix in tamsulosin hydrochloride sustained-release tablets and the tamsulosin hydrochloride sustained-release tablets. The coating premix is prepared from the following components in parts by weight: 40 to 60 parts of eudragit RS100, 20 to 30 parts of eudragit RL100, 10 to 15 parts of plasticizer, 15 to 20 parts of coloring agent, 15 to 20 parts of anti-sticking agent and 500 to 600 parts of solvent; the eudragit RS100 comprises ethyl acrylate, methyl methacrylate and methacrylic acid chlorinated trimethylamino ethyl ester, and the eudragit RL100 comprises ethyl acrylate, methyl methacrylate and methacrylic acid chlorinated trimethylamino ethyl ester; through application of the coating premix in the tamsulosin hydrochloride sustained-release tablet, the problems that the existing tamsulosin hydrochloride sustained-release tablet cannot be dissolved in the intestinal tract and the bioavailability of the medicine cannot be ensured are solved.

1. The name of the design product: medicine packaging box (sustained-release morphine hydrochloride tablets). 2. The use of the design product: medicine packaging box. 3. The design points of the design product: in the pattern. 4. The picture or photo that best indicates the design points: front view.

According to the trazodone hydrochloride sustained release tablet and the preparation method thereof, high-viscosity hydroxypropyl methylcellulose and low-viscosity hydroxypropyl methylcellulose are combined to serve as a sustained release material, the sustained release tablet can play a synergistic role to form a double-skeleton structure, so that medicine is stably released at a constant speed within 12-24 hours, and the sustained release effect is good. The sustained-release tablet can accurately regulate and control the drug release speed and reduce the fluctuation of blood concentration, so that the drug taking frequency is reduced to once a day, the risk of adverse reactions such as dizziness and drowsiness is reduced, the curative effect, compliance and safety of a patient are improved, and meanwhile, the sustained-release tablet is consistent in release behavior in different pH media, good in in-vivo absorption predictability and suitable for clinical application. Related substances grow slowly, the tablet stability is good, and the preparation method is simple, low in cost and suitable for industrial production.

The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and / or a SGLT-2 inhibitor drug, and metformin XR, processes for the preparation thereof, and their use to treat certain diseases.

The invention discloses a sitagliptin and metformin sustained release tablet without an antioxidant as well as a preparation method and application of the sitagliptin and metformin sustained release tablet. Relates to the field of medicine preparation. The sitagliptin and metformin pharmaceutical composition without the antioxidant comprises a tablet core and a coating, the tablet core comprises a sitagliptin layer and a metformin layer which are laminated; the sitagliptin layer and the metformin layer contain drug release pore channels; the metformin layer is prepared from the following components: metformin and an expansion material. According to the invention, through the dual design of the coating and the drug release pore channel, the drug has oxidation resistance and the characteristic of rapid release of the sitagliptin drug at the same time, the sitagliptin is ensured not to be oxidized under the condition that an antioxidant is not used, and rapid release of the sitagliptin is further realized, so that the treatment effect of taking effect rapidly is achieved. And meanwhile, the slow-release treatment effect of the metformin medicine is also considered.